Crimson Publishers- Novel Approaches in Cancer Study

A Molecular Perspective of Clinical Benefit: Why Shouldn’t Luminal a Breast Cancer Patients be Considered in Pathological Complete Response Discussions by Kieber Emmons T in Journal of Cancer Research   Crimson Publishers_   Novel Approaches in Cancer Study Breast cancer is a heterogeneous disease with biological subtypes having different prognostic impacts. This facet is particularly evident in Neoadjuvant trials where Pathological Complete Response (pCR) rates vary. Studies have shown that patients who achieve pCR after neoadjuvant treatment have a better long-term outcome. Consequently, increasing the rate of pCR became the end point of neoadjuvant trials with the expectation of translation into improved survival. However, for Luminal A subtype patients this is not the case, as this cohort does not respond to chemotherapy. Here we consider why this might be the case and several approaches that could change the paradigm treating this cohort. https://crimsonpublishers.com/nac...

Bridging the Gap between Pre-Clinical and Clinical Studies in Cancer Research by Ratna Kumari in Journal of Cancer Research   Crimson Publishers_   Novel Approaches in Cancer Study In spite of successful basic and pre-clinical cancer research findings its translatability into clinics is significantly low. Unfortunately, most of the clinical trials in oncology are unsuccessful and lead to pharmacological drug attrition. The complex nature of cancer biology and limitations due to pre-clinical research tools makes pre-clinical cancer research prone to irreproducibility. Pharmacological development of drugs heavily relies on the published data for drug target biology and irreproducible findings are the key factor behind high failure rates of clinical trials. Consequently, there is an urgent need to revisit the pre-clinical cancer research strategies to achieve a greater clinical success.  https://crimsonpublishers.com/nacs/fulltext/NACS.000545.php   For More Articles on...

  Modern Strategies in Cancer Study: Drug Repositioning in Colorectal Cancer Treatment by Menacho Márquez Mauricio in Journal of Cancer Research   Crimson Publishers_   Novel Approaches in Cancer Study Colorectal cancer is one of the most fatal cancers in the world because most of cases are diagnosed in advanced stages, when the development of resistance to chemotherapy is more frequent. To face this situation, new drugs and drug combinations would be necessary. Drug discovery is a very costly process; although efforts in drug discovery have been amplified in recent decades the success rate of approved FDA drugs continues being low. In response to this situation the repositioning of drugs proposes to delve into the genetic, epigenetic and metabolic differences to discover new targets and redirect drugs already approved to the treatment of other diseases and conditions. In this minireview we discuss the main avenues in which repositioning can occur and we cite some example...